SEOUL, South Korea and SHANGHAI, May 7, 2026 /PRNewswire/ — Taimei Technology (HK.02576), a leading AI-based clinical drug development platform company, and C&R Research (A359090), a leading CRO in South Korea, have signed an enterprise-level strategic partnership agreement, officially launching the development of an AI-based clinical trial operations system.
Under this partnership, C&R Research will deploy Taimei Technology’s cutting-edge digital infrastructure and AI agents across multiple clinical trials to automate and improve trial design and operational workflows. Particular emphasis will be placed on data management, where the EDC + iDM Agent combination will be actively adopted. Innovations such as intelligent data capture and governance, AI-driven eCRF generation, and automated test case creation are expected to boost the productivity and quality of clinical research.
Leveraging its full-stack AI capabilities, 13 years of industry expertise and global operational experience, Taimei Technology has deeply focused on the clinical research vertical and was among the first to create a comprehensive AI agent matrix, enabling scenario-based AI applications across the entire clinical research workflow. Key offerings include eCollect (EDC), eBalance (RTSM), eCOA, eCooperate (CTMS) and eArchives (eTMF), iDM Agent, iCTA Agent, iPV Agent; as well as the iMAP intelligent medical analysis platform andc. TThese products can be flexibly configured to address critical issues in clinical research, from efficacy to scientific insights, significantly improving trial efficiency and success rates.
The two companies plan to integrate AI-based operational models into Korea’s CRO-centric clinical trial execution system, creating a more efficient and intelligent clinical research framework.
Korea has established a mature ecosystem in innovative drug development and clinical execution, with clinical trial activities and global pipeline participation ranking among the best in the world. Industry observers believe that this partnership goes beyond technology adoption and will serve as a key catalyst to accelerate the digital transformation of South Korea’s clinical trial landscape, driven by AI.
Moon Tae YoonCEO of C&R Research, commented: “As clinical trials become increasingly complex, AI-driven data management and operational automation are emerging as critical competitive drivers. Through this partnership, we will build a more efficient and innovative clinical delivery system.
Zhao LuPresident of Taimei Technology, said: “This partnership represents an important opportunity to bring to South Korea the experience in AI clinical operations that we have accumulated in global markets. We look forward to collaborating with more Korean ecosystem partners to continuously drive the intelligent transformation of clinical trials.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/taimei-technology-and-cr-research-announce-strategic-partnership-to-build-ai-powered-clinical-trial-innovation-302758715.html
SOURCE Taimei Technology
